# A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors

> **NCT05491317** · PHASE1,PHASE2 · TERMINATED · sponsor: **Genmab** · enrollment: 13 (actual)

## Conditions studied

- Non-CNS Tumor

## Interventions

- **BIOLOGICAL:** GEN1042
- **DRUG:** Pembrolizumab
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT05491317
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-03-08
- **Primary completion:** 2025-08-11
- **Final completion:** 2025-08-11
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** After reviewing all available data from Part 1 of the trial, the Sponsor has decided not to proceed to Part 2 (randomized Phase 2) of the trial due to lack of efficacy
- **Last updated:** 2026-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05491317

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05491317, "A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05491317. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*